Report CSF Ab42 and tau in relation to amyloid in humans Lachno D, Vanderstichele H, Groote GD, Kostanjevecki V, Meyer GD, Siemers E, Willey M, Bourdage J, Konrad R, Dean R, (2009) The inﬂuence of matrix type, diurnal rhythm and sample collection and processing on the measurement of plasma beta-amyloid isoforms using the Inno-Bia Plasma Abeta Forms Multiplex Assay. J Nutr Health Aging 13: 220-225 Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, Jessen F, Bu¨rger K, Hampel H, Fr¨olich L et al (2009) Amyloid beta peptides in plasma in early diagnosis of Alzheimer’s disease: a multicenter study with multiplexing. Exp Neurol (in press), PMID:19664622 Lewis J, Dickson D, Lin W, Chisholm L, A A AC, Jones G, Yen S, Sahara N, Skipper L, Yager D et al (2001) Enhanced neuroﬁbrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293: 1487-1491 Li G, Sokal I, Quinn J, Leverenz J, Brodey M, Schellenberg G, Kaye J, Raskind M, Zhang J, Peskind E et al (2007) CSF tau/Ab42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 69: 631-639 Logan J, Fowler J, Volkow N, Wang G, Ding Y, Alexoff D, (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16: 834-840 Markesbery W, Schmitt F, Kryscio R, Davis D, Smith C, Wekstein D, (2006) Neuropathologic substrate of Mild Cognitive Impairment. Arch Neurol 63: 38-46 Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka S, Van der Flier WM, Blankenstein M, Ewers M et al (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302: 385-393 Mehta P, Pirttila T, (2005) Increased cerebrospinal ﬂuid Abeta38/Abeta42 ratio in Alzheimer’s disease. Neurodegener Dis 2: 242-245 Mintun M, LaRossa G, Sheline Y, Dence C, Lee S-Y, Mach R, Klunk W, Mathis C, DeKosky S, Morris J, (2006) [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67: 446-452 Morris J, McKeel D, Fulling K, Torack R, Berg L, (1988) Validation of clinical diagnostic criteria for Alzheimer’s disease. Ann Neurol 24: 17-22 Morris J, Price J, (2001) Pathologic correlates of nondemented aging, mild cognitive impairment, and early stage Alzheimer’s disease. J Mol Neurosci 17: 101-118 Morris J, Roe C, Grant E, Head D, Storandt M, Goate A, Fagan A, Holtzman D, Mintun M, (2009) PIB imaging predicts progression from cognitively normal to symptomatic Alzheimer’s disease. Arch Neurol (in press) Morris JC, (1993) The Clinical Dementia Rating (CDR). Current version and scoring rules. Neurology 43: 2412-2414 Oddo S, Caccamo A, Kitazawa M, Tseng B, LaFerla F, (2003a) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiol Aging 24: 1063-1070 Oddo S, Caccamo A, Shepherd J, Murphy M, Golde T, Kayed R, Metherate R, Mattson M, Akbari Y, LaFerla F, (2003b) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Aß and synaptic dysfunction. Neuron 39: 409-421 Price J, Ko A, Wade M, Tsou S, McKeel D, Morris J, (2001) Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer’s disease. Arch Neurol 58: 1395-1402 Price JL, Morris JC, (1999) Tangles and plaques in nondemented aging and ‘‘preclinical’’ Alzheimer’s disease. Ann Neurol 45: 358-368 Raﬁi M, Aisen P, (2009) Recent developments in Alzheimer’s disease therapeutics. BMC Med (in press) Salloway S, Mintzer J, Weiner M, Cummings J, (2008) Disease-modifying therapies in Alzheimer’s disease. Alzheimers Dement 4: 65-79 Schoonenboom N, Mulder C, Kamp GV, Mehta S, Scheltens P, Blankenstein M, Mehta P, (2005) Amyloid b 38, 40, and 42 species in cerebrospinal ﬂuid: more of the same? Ann Neurol 58: 139-142 Schupf N, Tang M, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R, (2008) Peripheral Abeta subspecies as risk biomarkers of Alzheimer’s disease. Proc Natl Acad Sci USA 105: 14052-14057 Snider B, Fagan A, Roe C, Shah A, Grant E, Xiong C, Morris J, Holtzman D, (2009) Cerebrospinal ﬂuid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 66: 638-645 Sunderland T, Mirza N, Putnam K, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J et al (2004) Cerebrospinal ﬂuid beta- amyloid -42 and tau in control subjects at risk for Alzheimer’s disease: the effect of APOE epsilon4 allele. Biol Psychiatry 56: 670-676 Welge V, Fiege O, Lewczul P, Mollenhauer B, Esselmann H, Klafki H-W, Wolf S, Trenkwalder C, Otto M, Kornhuber J et al (2009) Combined CSF tau, p- tau181 and amyloid-b 38/40/42 for diagnosing Alzheimer’s disease. J Neural Transm 116: 203-212 380 2009 EMBO Molecular Medicine EMBO Mol Med 1, 371–380 www.embomolmed.org